These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8642355)

  • 21. To prevent progression: ACE inhibitors, calcium antagonists or both?
    Stefanski A; Amann K; Ritz E
    Nephrol Dial Transplant; 1995; 10(2):151-3. PubMed ID: 7753444
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of diabetic nephropathy.
    Materson BJ; Preston RA
    Hosp Pract (1995); 1997 Feb; 32(2):129-34, 139-40. PubMed ID: 9040425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
    Durruty P; Tapia JC; Ugarte C; Pérez E; Krause P; Soto N; García de los Ríos M
    Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S; Girndt M; Köhler H
    Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract]   [Full Text] [Related]  

  • 25. [ACE inhibitors and kidney].
    Ritz E
    Wien Med Wochenschr; 1990 Jan; 140(1-2):18-21. PubMed ID: 2408246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
    Marre M; Garcia Puig J; Kokot F; Fernandez M; Jermendy G; Opie L; Moyseev V; Scheen A; Ionescu-Tirgoviste C; Saldanha MH; Halabe A; Williams B; Mion D; Ruiz M; Hermansen K; Tuomilehto J; Finizola B; Pozza G; Chastang C; Ollivier JP; Amouyel P; Asmar R
    J Hypertens Suppl; 2003 Mar; 21(1):S19-24. PubMed ID: 12769163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibitors and renal failure in diabetes.
    Hiremath S; Zimmerman D; Knoll GA
    Kidney Int; 2006 Oct; 70(7):1377; author reply 1378. PubMed ID: 16988744
    [No Abstract]   [Full Text] [Related]  

  • 35. Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension.
    Opie LH
    Lancet; 2001 Dec; 358(9296):1829-31. PubMed ID: 11741617
    [No Abstract]   [Full Text] [Related]  

  • 36. ACE inhibition in diabetic patients. Economic implications.
    Rodby RA; Lewis EJ
    Pharmacoeconomics; 1996 Oct; 10(4):315-20. PubMed ID: 10163576
    [No Abstract]   [Full Text] [Related]  

  • 37. Renoprotection with antihypertensive agents.
    Hilgers KF; Mann JF
    Lancet; 2002 May; 359(9318):1693; author reply 1693-4. PubMed ID: 12020551
    [No Abstract]   [Full Text] [Related]  

  • 38. [Diabetic nephropathy--manage now!].
    Ritz E
    Dtsch Med Wochenschr; 2010 Mar; 135(9):p8. PubMed ID: 20200822
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Walser M
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
    [No Abstract]   [Full Text] [Related]  

  • 40. Microalbuminuria and ACE inhibition in non-hypertensive diabetics.
    Marre M
    J Diabet Complications; 1990; 4(2):84-5. PubMed ID: 2145309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.